Home
FEMY
FEMY News

Latest Femasys Inc. (FEMY) News on June 27, 2025

MT Newswires

2 days ago

Femasys Says FemBloc Non-Surgical Permanent Birth Control Gets European Approval; Shares Rise

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

GlobeNewswire

2 days ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

GlobeNewswire

10 days ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

GlobeNewswire

16 days ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million

GlobeNewswire

a month ago

Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million

MT Newswires

a month ago

Femasys Plans Public Offering, Concurrent Private Placement

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

GlobeNewswire

a month ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Zacks

2 months ago

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

GlobeNewswire

2 months ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates

Zacks

3 months ago

Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

GlobeNewswire

3 months ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Femasys price target raised to $15 from $12 at H.C. Wainwright

TipRanks

3 months ago

Femasys price target raised to $15 from $12 at H.C. Wainwright

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

GlobeNewswire

3 months ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

ACCESS Newswire

3 months ago

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

MT Newswires

3 months ago

Femasys Signs FemBloc Commercial Distribution Deals

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

GlobeNewswire

3 months ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

GlobeNewswire

4 months ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

GlobeNewswire

4 months ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

GlobeNewswire

5 months ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Femasys gains approvals for infertility and diagnostic products in Israel

Medical Device Network

5 months ago

Femasys gains approvals for infertility and diagnostic products in Israel

Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

GlobeNewswire

5 months ago

Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

GlobeNewswire

5 months ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

MT Newswires

5 months ago

Femasys Gets Notice of Allowance for New US FemaSeed Patent

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

GlobeNewswire

5 months ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed

GlobeNewswire

7 months ago

Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

GlobeNewswire

7 months ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Femasys Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

7 months ago

Femasys Third Quarter 2024 Earnings: Misses Expectations

Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates

Zacks

7 months ago

Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

GlobeNewswire

7 months ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys to Exhibit at the Annual AAGL 2024 Global Conference

GlobeNewswire

8 months ago

Femasys to Exhibit at the Annual AAGL 2024 Global Conference

MT Newswires

8 months ago

Femasys Says It Received US Patent for Female Birth Control Device FemBloc

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

GlobeNewswire

8 months ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed

GlobeNewswire

8 months ago

Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed

Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program

GlobeNewswire

9 months ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program

Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire

9 months ago

Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

GlobeNewswire

9 months ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Femasys Announces Infertility Clinic Customers from Coast to Coast

GlobeNewswire

9 months ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

GlobeNewswire

10 months ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device

Zacks

10 months ago

Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device

MT Newswires

10 months ago

Femasys Permanent Birth Control Solution Gets 510(k) Clearance

FDA clears FemChec for fallopian tube occlusion testing

Medical Device Network

10 months ago

FDA clears FemChec for fallopian tube occlusion testing

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

GlobeNewswire

10 months ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting

GlobeNewswire

10 months ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting

Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI

Zacks

10 months ago

Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

10 months ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Femasys secures CE mark certification for FemVue MINI solution

Medical Device Network

10 months ago

Femasys secures CE mark certification for FemVue MINI solution

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

GlobeNewswire

10 months ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

GlobeNewswire

10 months ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Femasys Second Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

a year ago

Femasys Second Quarter 2024 Earnings: Misses Expectations

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

Zacks

a year ago

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

GlobeNewswire

a year ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

GlobeNewswire

a year ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Femasys gains CE Mark approval for women’s health products

Medical Device Network

a year ago

Femasys gains CE Mark approval for women’s health products

MT Newswires

a year ago

Femasys Secures CE Mark Approvals for Four Women's Health Products; Shares Up Over 14%

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

GlobeNewswire

a year ago

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

GlobeNewswire

a year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council

GlobeNewswire

a year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Zacks

a year ago

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

GlobeNewswire

a year ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

GlobeNewswire

a year ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know

Zacks

a year ago

Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives

GlobeNewswire

a year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives

Femasys Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a year ago

Femasys Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

GlobeNewswire

a year ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

GlobeNewswire

a year ago

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

GlobeNewswire

a year ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024

GlobeNewswire

a year ago

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

GlobeNewswire

a year ago

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

GlobeNewswire

a year ago

Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

GlobeNewswire

a year ago

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Battery & Precious Metals Virtual Investor Conference: Presentations Now Available for Online Viewing

GlobeNewswire

a year ago

Battery & Precious Metals Virtual Investor Conference: Presentations Now Available for Online Viewing

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mullen Opens Dominican Republic and Caribbean Markets for Commercial EVs

GlobeNewswire

a year ago

Mullen Opens Dominican Republic and Caribbean Markets for Commercial EVs

Comstock Inc. to Present at the Battery & Precious Metals Virtual Investor Conference on January 30, 2024

GlobeNewswire

a year ago

Comstock Inc. to Present at the Battery & Precious Metals Virtual Investor Conference on January 30, 2024

Associated Press Finance

a year ago

Territorial Bancorp: Q4 Earnings Snapshot

Territorial Bancorp Inc. Declares Dividend

GlobeNewswire

a year ago

Territorial Bancorp Inc. Declares Dividend

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

GlobeNewswire

a year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

LION ELECTRIC INITIATES DELIVERIES OF LIOND, A NEW ALL-ELECTRIC SCHOOL BUS MODEL

PR Newswire

a year ago

LION ELECTRIC INITIATES DELIVERIES OF LIOND, A NEW ALL-ELECTRIC SCHOOL BUS MODEL

11 Hyper-Growth Stocks Billionaires Are Loading Up On

Insider Monkey

a year ago

11 Hyper-Growth Stocks Billionaires Are Loading Up On

Vroom, Lockheed Martin, Fisker: Trending Tickers

Yahoo Finance Video

a year ago

Vroom, Lockheed Martin, Fisker: Trending Tickers

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

GlobeNewswire

a year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

Sphere 3D Announces Agreement with Core Scientific

Newsfile

a year ago

Sphere 3D Announces Agreement with Core Scientific

Cosmic Gains? 3 Space Stocks Worth a Closer Look.

InvestorPlace

a year ago

Cosmic Gains? 3 Space Stocks Worth a Closer Look.

Mobix Labs Begins Delivery of Guidance System Components for Use in the U.S. Army’s Javelin Missile System

Business Wire

a year ago

Mobix Labs Begins Delivery of Guidance System Components for Use in the U.S. Army’s Javelin Missile System

Good Times Restaurants Reports First Fiscal Quarter Same Store Sales

Business Wire

a year ago

Good Times Restaurants Reports First Fiscal Quarter Same Store Sales

Smith Micro Retires Senior Secured Convertible Notes

Business Wire

a year ago

Smith Micro Retires Senior Secured Convertible Notes

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

GlobeNewswire

a year ago

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

Newsfile

a year ago

Snow Lake Lithium CEO Update to Shareholders

UEI Announces a Better Smart Home Control Experience with a Complete Line-Up of White Label Smart Home Hubs & Sensors

Business Wire

a year ago

UEI Announces a Better Smart Home Control Experience with a Complete Line-Up of White Label Smart Home Hubs & Sensors

Bronzed Beauty Meets Power: ECD Auto Design’s Newest Defender 110 Features a 450-HP LT1 V8-Engine

GlobeNewswire

a year ago

Bronzed Beauty Meets Power: ECD Auto Design’s Newest Defender 110 Features a 450-HP LT1 V8-Engine

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

GlobeNewswire

a year ago

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

Business Wire

a year ago

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

Affimed Announces Leadership Change and Organizational Restructuring

GlobeNewswire

a year ago

Affimed Announces Leadership Change and Organizational Restructuring

Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue

GlobeNewswire

a year ago

Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue

US Global Investors Inc's Dividend Analysis

GuruFocus.com

a year ago

US Global Investors Inc's Dividend Analysis

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire

a year ago

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ACCESSWIRE

a year ago

iAccess Alpha Tax Loss Recovery Summit 2024 - Buyside Best Ideas January 9th-10th 2024

Mobix Labs Awarded M-1 Abrams Tank Contract for U.S. Army

GlobeNewswire

a year ago

Mobix Labs Awarded M-1 Abrams Tank Contract for U.S. Army

Global Systems Dynamics, Inc.’s Provides Update on Nasdaq Compliance Status and Process

GlobeNewswire

a year ago

Global Systems Dynamics, Inc.’s Provides Update on Nasdaq Compliance Status and Process

Snail Games' ARKade Ambassador Program Reshapes Gaming Connections

GlobeNewswire

a year ago

Snail Games' ARKade Ambassador Program Reshapes Gaming Connections

Share on Social Networks: